Gemzar and Walking disability - a phase IV clinical study of FDA data

Summary:

Walking disability is reported as a side effect among people who take Gemzar (gemcitabine hydrochloride), especially for people who are female, 50-59 old, also take Mupirocin, and have Hypercalcaemia.

The phase IV clinical study analyzes which people have Walking disability when taking Gemzar. It is created by eHealthMe based on reports of 20,184 people who have side effects when taking Gemzar from the FDA, and is updated regularly.

What is Gemzar?

Gemzar has active ingredients of gemcitabine hydrochloride. It is often used in pancreatic carcinoma. eHealthMe is studying from 20,315 Gemzar users. Check the latest studies of Gemzar.

What is Walking disability?

Walking disability is found to be associated with 290 drugs and 813 conditions by eHealthMe. Check the latest studies of Walking disability.

On Aug, 04, 2026

20,184 people reported to have side effects when taking Gemzar.
Among them, 23 people (0.11%) have Walking disability.

Among these 23 people:

What is the gender of people who have Walking disability when taking Gemzar? *

female: 95.65 %
male: 4.35 %

What is the age of people who have Walking disability when taking Gemzar? *

What are other drugs people take besides Gemzar? *

What are other side effects people have besides Walking disability? *

Wound Infection Staphylococcal: 23 people, 100.00%
Ingrowing Nail: 23 people, 100.00%
Osteitis (a general term for inflammation of bone): 23 people, 100.00%
Oral Mucosal Exfoliation (removal of mucous membrane of mouth): 23 people, 100.00%
Oral Disorder (mouth disease): 23 people, 100.00%
Oedema Peripheral (superficial swelling): 23 people, 100.00%
Nuclear Magnetic Resonance Imaging Abnormal: 23 people, 100.00%
Night Sweats (sweating in night): 23 people, 100.00%
Neuralgia (pain in one or more nerves): 23 people, 100.00%
Mitral Valve Prolapse (heart's mitral valve doesn't work well): 23 people, 100.00%

What are the existing conditions these people have? *

Hypercalcaemia (elevated calcium (ca+) level in the blood): 23 people, 100.00%
Breast Cancer Metastatic: 22 people, 95.65%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 4.35%
Migraine (headache): 1 person, 4.35%
Metastases To Bone (cancer spreads to bone): 1 person, 4.35%

* Approximation only. Some reports may have incomplete information.

Do you take Gemzar and have Walking disability?

- Check whether Walking disability is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemzar:

Gemzar (20,315 reports)

Browse all side effects of Gemzar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Walking disability:

Walking disability (290 drugs)

Browse all the conditions that are associated with Walking disability:

Walking disability (813 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gemcitabine hydrochloride (the active ingredients of Gemzar) and Gemzar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.